Combined Botulinum Toxin Type A With Modified Constraint-Induced Movement Therapy for Chronic Stroke Patients With Upper Extremity Spasticity: A Randomized Controlled Study

Abstract

Background and objective . Botulinum toxin type A (BtxA) injection and modified constraint-induced movement therapy (mCIMT) are both promising approaches to enhance recovery after stroke. The combined application of these 2 promising modalities has rarely been studied. The aim was to investigate whether combined BtxA and mCIMT would improve spasticity and upper extremity motor function more than BtxA plus conventional rehabilitation in chronic stroke patients with upper extremity spasticity. Methods. In a prospective, randomized controlled, observer-blinded trial with 6-month follow-up, 32 patients (≥1 year after stroke) with ability to actively extend >10° at metacarpophalangeal and interphalangeal joints and 20° at wrist of the affected upper limb were randomized to receive BtxA + mCIMT (combination group) or BtxA + conventional rehabilitation (control group) for 2 hours/day, 3 days/week for 3 months.The primary outcome assessed spasticity on the Modified Ashworth Scale. Secondary outcomes assessed real-world arm function (Motor Activity Log), laboratory motor activity (Action Research Arm Test), and patients’ global satisfaction. Results. A total of 32 stroke patients were recruited, and 29 completed the study. Spasticity significantly improved in all subjects at 4 weeks and 3 months postinjection without between-group differences.The combination group showed significantly greater improvements in elbow, wrist, and finger spasticity (P = .019, P = .019, and P < .001, respectively), affected upper extremity real-world arm function (P < .001) and laboratory motor activity (P < .001) than the control group at 6-month postinjection. Patients reported considerable satisfaction and no serious adverse events occurred. Conclusions. Combining BtxA and mCIMT is an effective and safe intervention for improving spasticity and motor function in chronic stroke patients. The results are promising enough to justify further studies. We recommend future research to address the likely need for including rehabilitation with BtxA to improve function in patients with poststroke spasticity.

Keywords

botulinum toxin constraint-induced movement therapy spasticity stroke rehabilitation

References

Wade DT , Collen FM , Robb GF , Warlow CP Physiotherapy intervention late after stroke and morbidity. BMJ. 1992;304: 609-613.

Simpson DM , Alexander DN , O’Brien CF , et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology . 1996;46:1306-1310.

Bakheit AM , Thilmann AF , Ward AB , et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb muscle spasticity after stroke . Stroke. 2000;31:2402-2406.

Bhakta BB , Cozens JA , Chamberlain MA , Bamford JM , et al. Impact of botulinum toxin on disability and carer burden due to arm spasticity after stroke: a randomized double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000 ;69: 217-221.

Brashear A. , Gordon MF , Elovic E. , et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med . 2002;347:395-400.

Sahrmann SA , Norton BJ The relationship of voluntary movement to spasticity in the upper motor neuron syndrome. Trans Am Neurol Assoc. 1977;102:108-111.

Knutsson E. , Martensson A. Dynamic motor capacity in spastic paresis and its relation to prime mover dysfunction, spastic reflexes and agonist co-activation. Scand J Rehabil Med. 1980;12:93-106.

Page SJ , Elovic E. , Levine P. , Sisto SA Modified constraint-induced therapy and botulinum toxin A: a promising combination . Am J Phys Med Rehabil. 2003;82:76-80.

Taub E. , Uswatte G. , Pidikiti R. Constraint-induced movement therapy: a new family of techniques with broad application to physical rehabilitation-a clinical review. J Rehabil Res Dev. 1999;36:237-251.

10.

van der Lee JH , Wagenaar RC , Lankhorst GJ , Wogelaar TW , Devillé WL , Bouter LM Forced use of the upper extremity in chronic stroke patients: results from a single-blind randomized clinical trial. Stroke. 1999;30:2369-2375.

11.

Wolf SL , Winstein CJ , Miller JP , et al; EXCITE investigators. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA. 2006;296:2095-2104.

12.

Lin KC , Wu CY , Liu JS , Chen YT , Hsu CJ Constraint-induced therapy versus dose-matched control intervention to improve motor ability, basic/extended daily functions, and quality of life in stroke . Neurorehabil Neural Repair. 2009;23:160-165.

13.

Miltner WH , Bauder H. , Sommer M. , Dettmers C. , Taub E. Effects of constraint-induced movement therapy on patients with chronic motor deficits after stroke: a replication. Stroke. 1999;30:586-592.

14.

Page SJ , Sisto SA , Levine P. , Johnston MV , Hughes M. Modified constraint induced therapy: a randomized, feasibility and efficacy study. J Rehabil Res Dev. 2001;38:583-590.

15.

Page SJ , Sisto S. , Levine P. , McGrath RE Efficacy of modified constraint induced therapy in chronic stroke: a single blinded randomized controlled trial. Arch Phys Med Rehabil . 2004;85:14-18.

16.

Page SJ , Levine P. , Leonard AC Modified constraint-induced therapy in acute stroke: a randomized controlled pilot study. Neurorehabil Neural Repair. 2005 ;19:27-32.

17.

Sun SF , Hsu CW , Hwang CW , Hsu PT , Wang JL , Yang CL Application of combined botulinum toxin type A and modified constraint-induced movement therapy for an individual with chronic upper-extremity spasticity after stroke. Phys Ther. 2006;86:1387-1397.

18.

Bohannon RW , Smith MB Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 ;67:206-207.

19.

Bleecker ML , Bolla-Wilson K. , Kawas C. , Agnew J. Age-specific norms for the Mini-Mental State Exam. Neurology. 1988;38:1565-1568.

20.

Gregson JM , Leathley M. , Moore AP , Sharma AK , Smith TL , Watkins CL Reliability of the tone assessment scale and the modified Ashworth scale as clinical tools for assessing poststroke spasticity. Arch Phys Med Rehabil. 1999;80:1013-1016.

21.

Uswatte G. , Taub E. , Morris D. , Vignolo M. , McCulloch K. Reliability and validity of the upper-extremity Motor Activity Log-14 for measuring real-world arm use. Stroke. 2005 ;36:2493-2496.

22.

van der Lee J. , Beckerman H. , Knol D. , de Vet HC , Bouter LM Clinimetric properties of the motor activity log for the assessment of arm use in hemiparetic patients. Stroke. 2004;35:1-5.

23.

Lyle RC A performance test for assessment of upper limb function in physical rehabilitation treatment and research. Int J Rehabil Res. 1981;4:483-492.

24.

van der Lee JH , De Groot V. , Beckerman H. , Wagenaar RC , Lankhorst GJ , Bouter LM The intra- and interrater reliability of the Action Research Arm test: a practical test of upper extremity function in patients with stroke. Arch Phys Med Rehabil. 2001;82:14-19.

25.

Albright AL , Barron WB , Fasick MP , Polinko P. , Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA. 1993;270:2475-2477.

26.

Jankovic J. , Schwartz K. Botulinum toxin injections for cervical dystonia . Neurology. 1990;40:277-280.

27.

de Paiva A. , Meunier FA , Molgo J. Functional repair of motor endplates after botulinum toxin-A poisoning: bi-phasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200-3205.

28.

Hesse S. , Jahnke MT , Luecke D. , Mauritz KH Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett. 1995;201:37-40.

29.

Eleopra R. , Tugnoli V. , De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov Disord. 1997;12:89-94.

30.

Jørgensen HS , Nakayama H. , Raaschou HO , Vive-Larsen J. , Støier M. , Olsen TS Outcome and time course of recovery in stroke. Part II: time course of recovery. The Copenhagen Stroke Study. Arch Phys Med Rehabil. 1995;76:406-412.

31.

Levy CE , Giuffrida C. , Richards L. , Wu S. , Davis S. , Nadeau SE Botulinum toxin A, evidence-based exercise therapy, and constraint-induced movement therapy for upper-limb hemiparesis attributable to stroke: a preliminary study. Am J Phys Med Rehabil. 2007;86:696-706.